Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC
ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC
IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC
FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations
IASLC 2021: Antibody Response to SARS–CoV-2 Vaccination in Patients With Lung Cancer
IASLC 2021: POSEIDON Trial of Durvalumab Plus Tremelimumab in Metastatic NSCLC
Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer
Autologous Tumor-Infiltrating Lymphocyte Treatment Under Study in Metastatic NSCLC
Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC
Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?
TP53-Mutated Non–Small Cell Lung Cancer and Airborne Pollutants
Does the Use of Metformin Improve Outcomes in Patients With Non–Small Cell Lung Cancer?
IASLC Consensus Statement on Liquid Biopsy for Patients With Advanced NSCLC
Atezolizumab Receives Priority Review From the FDA in Early NSCLC
PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC
Can Postoperative Radiotherapy Improve Survival Outcomes in Patients With NSCLC?
Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC
Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?
Preliminary Results With Novel EGFR Inhibitor for EGFR-Mutated Lung Cancer
Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer
Breakthrough Therapy Designation Given to Adagrasib for KRAS G12C–Mutated NSCLC
Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?
ASCO 2021: LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer
ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer
AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer
Is KRAS Status Linked to Response to Immunotherapy for Advanced Lung Cancer?
ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer
Robotic Bronchoscopy May Improve Timing and Accuracy of Lung Cancer Diagnosis
ASCO 2021: Video-Assisted Thoracoscopy Versus Open Lobectomy for Early-Stage Lung Cancer
$20 Million Donation to MSK to Support Lung Cancer Research
ASCO 2021: Subgroup Efficacy Analysis of Sotorasib for Advanced KRAS G12C–Mutated NSCLC
ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC
Anti–PD-1 Monoclonal Antibody Plus Chemotherapy for Advanced Squamous NSCLC
Sotorasib Receives Approval for NSCLC With KRAS G12C Mutations
FDA Accepts Submission for Sintilimab in Combination With Pemetrexed/Platinum Chemotherapy in NSCLC
Does Performance Status Correlate With Survival in Pembrolizumab-Treated Patients With NSCLC?
FDA Approves Targeted Therapy Amivantamab-vmjw for Subset of NSCLC
ASCO 2021: Atezolizumab in Early-Stage Resected NSCLC After Chemotherapy
RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC
Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC
AACR 2021: Influence of Aneuploidy on Response to Immunotherapy for Lung Cancer
AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC
EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.